Rollins John Woodson bought AIDX
February 19, 2026 · Form 4 insider transaction
Rollins John Woodson bought 6,135 shares of 20/20 Biolabs, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 4 days after the transaction.
Direction
Acquired (buy-side)
Shares
6,135
Price
$0.00
Total value
N/A
InsiderRollins John Woodson
Role—
Company20/20 Biolabs, Inc. (AIDX)
SecurityCommon Stock
Transaction codeC: Conversion of a derivative
Transaction dateFebruary 19, 2026
Filing dateFebruary 23, 2026
Shares owned after30,275
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date.